Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
To Live a Sparkly Life
It’s been a couple of months now, and I’m pleased to say I am tolerating the new drug, Carfilzomib, brand name Kyprolis, very well. I’m now on the ‘Dara’ (Daratumumab AKA Darzolex) just once a month, but I’m getting the Kyprolis 6 times every three weeks, so I am getting to know my nurses very well! The Kyprolis visits are relatively short, lasting an hour to 2 hours each time, depending on whether we are doing lab work, etc.
On the Dara day each month, the Kyprolis adds another 10 minutes onto the 5 hour visit. The Dara days are the nap days. I’m still getting nothing done, but it is incredibly relaxing as the Benedryl takes hold and I’m off to a delicious dreamland for an hour or two or three.
Source: https://toliveasparklylife.com/
myBinderRelated Content
-
Efficacy of Different Modes of Fractional CO2 Laser in the Treatment of Primary Cutaneous Amyloidosis: A Randomized ...Background: Primary cutaneous amyloidos...
-
How Can I Cope With Diarrhoea?Patients should tell the medical staff a...
-
Paul Cheng, MD, PhDDr. Cheng is a Cardiologist and Instru...
-
UCLA HealthUCLA Health is among the most comprehens...
-
Combination Therapy Holds Promise for Newly Diagnosed Systemic AL Amyloidosis PatientsUpdated research regarding the ANDROMEDA...
-
Anita D’Souza, MD, MSAnita D’Souza is an Associate Professo...
-
Cardiac Amyloidosis Program at Brigham and Women’s HospitalThe Cardiac Amyloidosis Program at Brigh...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
